Le Lézard
Classified in: Health
Subject: CCA

Ionis to present at upcoming investor conferences


CARLSBAD, Calif., April 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionispharma.com and follow us on X (Twitter) and LinkedIn.

SOURCE Ionis Pharmaceuticals, Inc.


These press releases may also interest you

at 07:30
Quipt Home Medical Announces Normal Course Issuer Bid
Quipt Home Medical Corp. (the "Company") ?, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announced today that the Toronto Stock Exchange ("TSX") has accepted the Company's notice of intention to implement a...

at 07:30
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will present long-term efficacy, safety and...

at 07:30
MedBright AI Announces New Commercial Product Demos for MedMatrix AI Platform
MedBright AI Investments Inc. (the "Company" or "MedBright") today announced MedMatrix, a product in which it has a significant investment, has launched two new demonstration videos highlighting the capabilities of the MedMatrix AI Reporter and...

at 07:30
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally...

at 07:30
VitalHub Announces Q1 2024 Conference Call Date
VitalHub Corp. (the "Company" or "VitalHub") is pleased to announce that it will release its financial results for its first quarter 2024 ended March 30th, 2024, after market close on May 9th, 2024. The Company will subsequently hold a conference...

at 07:25
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
Arbutus Biopharma Corporation ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today...

More news about Health...


News published on and distributed by: